Skip to main content
. Author manuscript; available in PMC: 2011 Jun 4.
Published in final edited form as: Nat Rev Endocrinol. 2009 Nov;5(11):611–619. doi: 10.1038/nrendo.2009.196

Figure 1.

Figure 1

Serum phosphate lowering effects of FGF23. FGF23 (produced in the bone) can suppress NaPi-2a and NaPi-2c cotransporters, which results in increased renal excretion of phosphate. Similarly, FGF23 can suppress renal expression of 1-α hydroxylase, which leads to reduced production of calcitriol and decreased intestinal phosphate absorption, and subsequent reduced serum levels of phosphate.